PET500 at Leading US Trade Show

RNS REACH

Futura Medical plc

("Futura" or "the Company")

PET500 showcased at leading US trade show

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that its innovative spray for enhanced sexual control, PET500, has been showcased by its commercial partner at the annual Marketplace meeting of the US National Association of Chain Drug Stores (NACDS) in Denver, Colorado.

Marketplace, which this year was held on 23 to 26 June, is the largest conference of its type in the USA. It is attended by the decision makers from the food, drug and mass retail industries who together purchase products worth more than US$500 billion annually.

Presentations about the clinical performance and commercial potential of PET500 were made to the key retailers at Marketplace prompting positive feedback. Showcasing of innovative products at Marketplace is part of the product launch process.

PET500, a topical spray that combines Futura's DermaSys® AquaFree delivery system with a mild topical anaesthetic, is designed to delay male ejaculation and to take effect quickly.

James Barder, Futura's Chief Executive, said: "We are very encouraged by the initial reaction to PET500 at this major US trade show ahead of the phased roll-out of the product in the USA."

For any further information please contact:

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com